| Ixabepilone | advanced breast cancer (metastatic), in no longer responding to currently available chemotherapies | vs no ixabepilone | death (overall survival) by 10% suggested progression or death (progression free survival PFS) by 25% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| death (overall survival) | 0.90 [0.81 1.00] | p=0.04 | 0 | 734 | 2 | Sparano, Thomas, | | progression or death (progression free survival PFS) | 0.75 [0.64 0.88] | p=0.04 | 0 | 752 | 1 | Thomas, | | toxicity grade 3-4 | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Sparano, 2010 | ixabepilone (40 mg/m(2) intravenously on day 1) plus capecitabine (2,000 mg/m(2) orally on days 1 through 14) given every 21 days | capecitabine alone (2,500 mg/m(2) on the same schedule) given every 21 days | patients with metastatic breast cancer previously treated with anthracycline and taxanes | | Thomas, 2007 | ixabepilone 40 mg/m(2) intravenously on day 1 of a 21-day cycle plus capecitabine 2,000 mg/m(2) orally on days 1 through 14 of a 21-day cycle | capecitabine alone 2,500 mg/m(2) on days 1 through 14 of a 21-day cycle | patients with metastatic breast cancer progressing after anthracycline and taxane treatment |
| |
